Z Contains A Cyclopentyl Or Cyclopentene Ring Patents (Class 514/530)
  • Publication number: 20140171490
    Abstract: Disclosed is the use of a mist of a pharmaceutical composition for ophthalmic delivery of a protein or peptide active pharmaceutical ingredient, a related method of treatment and a device useful in implementing the use and method. Disclosed is also the use of a mist for ophthalmic delivery of a pharmaceutical composition including a highly irritating penetration enhancer and an ophthalmically acceptable carrier, a related method of treatment and a device useful in implementing the use and method. Disclosed is also a device for ophthalmic administration configured to direct a mist of a pharmaceutical composition to the eye only when the eye is open. Disclosed is also a self-sterlizing device for ophthalmic administration. Disclosed is also a device and a method for increasing the bioavailability of an ophthalmically administered API in a pharmaceutical composition.
    Type: Application
    Filed: August 9, 2013
    Publication date: June 19, 2014
    Applicant: PHARMALINGT INC.
    Inventors: Yossi Gross, Rafi Herzog, Steven B. Koevary
  • Publication number: 20140171496
    Abstract: The present invention provides a method and composition for promoting hair growth in a mammal which comprises a prostaglandin compound having two hetero atoms at the 15 position as an active ingredient thereof.
    Type: Application
    Filed: February 7, 2014
    Publication date: June 19, 2014
    Applicant: R-Tech Ueno, Ltd.
    Inventors: Ryuji UENO, Tsuyoshi HABE, Takashi SEKIDA
  • Publication number: 20140171388
    Abstract: The present invention provides a compound of which active |form| is represented by a formula (A). and which can be injected into a joint cavity which is an affected part of disorders and can be accumulated in the joint cavity to exert the pharmacological effect thereof in a sustained manner, for the purpose of ameliorating cartilage disorders without developing any side effect. A compound according to the present invention, which is represented by a formula (I): (wherein all of symbols are as defined in the description), is a compound that can achieve the above-mentioned purpose. This compound does not exhibit any side effect on the cardiovascular system even when the compound is administered in an effective amount for exhibiting a cartilage regeneration activity, and is therefore extremely useful as a safe and effective preventive and/or therapeutic agent for cartilage disorders.
    Type: Application
    Filed: August 3, 2012
    Publication date: June 19, 2014
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tetsuo Obitsi, Kousuke Tani, Hikaru Sugihara, Akio Nishiura, Shinsei Fujimura
  • Patent number: 8754123
    Abstract: The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil.
    Type: Grant
    Filed: April 9, 2012
    Date of Patent: June 17, 2014
    Assignee: Alcon Research, Ltd.
    Inventor: Bhagwati P. Kabra
  • Publication number: 20140163098
    Abstract: The present invention relates to compositions, such as bimatoprost, latanoprost and travoprost, and methods to reduce fat in the body of an individual, for example, by topical administration, injection, and/or implantation of such compositions.
    Type: Application
    Filed: February 13, 2014
    Publication date: June 12, 2014
    Applicant: Topokine Therapeutics, Inc.
    Inventors: Cynthia L. Grosskreutz, Louis R. Pasquale, Michael S. Singer, Murat V. Kalayoglu
  • Publication number: 20140161863
    Abstract: A drug insert is configured for use with an implant. The implant is configured for insertion into a lacrimal canaliculus. The drug insert includes a drug core comprising a therapeutic agent and a polymer; and a sheath body comprising material substantially impermeable to the therapeutic agent, wherein the drug core is positioned within the sheath body. The sheath body is configured to provide an exposed end of the drug core that releases therapeutic agent to an eye when the drug insert is disposed within the implant and the implant is positioned in the lacrimal canaliculus. A distal end of the drug core is sealed with a medical-grade adhesive.
    Type: Application
    Filed: February 14, 2014
    Publication date: June 12, 2014
    Applicant: Mati Therapeutics, Inc.
    Inventors: Eugene De Juan, JR., Stephen Boyd, Hanson S. Gifford, III, Mark Deem, Cary J. Reich
  • Patent number: 8722735
    Abstract: The present invention is directed to the provision of pharmaceutical compositions. The compositions include a therapeutic agent and a relatively low amount of surfactant for providing higher bioavailability of the therapeutic agent. The compositions are particularly desirable as ophthalmic compositions in which the therapeutic agent is a prostaglandin such as travoprost and the surfactant is a vegetable oil such as castor oil.
    Type: Grant
    Filed: October 4, 2011
    Date of Patent: May 13, 2014
    Assignee: Alcon Research, Ltd.
    Inventors: Bhagwati P. Kabra, Nuria Carreras, Mónica Cuchi, Francisco Javier Galán, Mridvika, Elena González Puig, Nuria Jiménez, Carmen Martinez
  • Patent number: 8722739
    Abstract: The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them.
    Type: Grant
    Filed: October 29, 2008
    Date of Patent: May 13, 2014
    Assignee: Novaer Holdings, Inc.
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant
  • Patent number: 8715713
    Abstract: The present invention provides a sustained release latanoprost implant in the form of a thin film comprising latanoprost incorporated in a biodegradable polymer matrix. Preferably, said implant is an intraocular implant comprising a thin film comprising latanoprost incorporated in a biodegradable polymer matrix wherein said implant is configured as a disc or a rolled film that can be inserted into the eye and unrolls to provide a film having a high surface area to volume ratio.
    Type: Grant
    Filed: April 27, 2012
    Date of Patent: May 6, 2014
    Assignee: Allergan, Inc.
    Inventors: Alazar N. Ghebremeskel, Lon T. Spada
  • Publication number: 20140112970
    Abstract: The methods described herein provide treatment of glaucoma, ocular hypertension, and elevated intraocular pressure with latanoprost or other therapeutic agent(s). Implant devices for insertion into a punctum of a patient provide sustained release of latanoprost or other therapeutic agent(s) that is maintained for 7, 14, 21, 30, 45, 60, or 90 days or more, thus avoiding patient noncompliance and reducing or lowering adverse events associated with eye drop administration of latanoprost or other therapeutic agent(s) and other therapeutic agent(s).
    Type: Application
    Filed: December 20, 2013
    Publication date: April 24, 2014
    Applicant: MATI THERAPEUTICS, INC.
    Inventor: Zuhal Butuner
  • Publication number: 20140107195
    Abstract: A water-swellable linear polyurethane polymer is formed by reacting a polyethylene oxide (e.g. PEG 4000 to 35,000), a difunctional compound (e.g. a diamine or diol such as 1,10-decanediol) with a diisocyanate. The ratio of the three components is generally in the range 0.1-1.5 to 1 to 1.1-2.5. The polyurethane is water-swellable in the range 300 to 1700% and soluble in certain organic solvents such as dichloromethane. It can be loaded with pharmaceutically active agents, particularly of high molecular weight, to produce controlled release compositions, such as pessaries etc.
    Type: Application
    Filed: December 6, 2013
    Publication date: April 17, 2014
    Applicant: Ferring B.V.
    Inventors: Janet Anne Halliday, Jukka Tuominen, Mark Alexander Livingstone, Frank Koppenhagen, Lilias Morton Currie, Sarah Stewart
  • Publication number: 20140105957
    Abstract: The present invention relates to an ocular polymer delivery composition comprising at least one ophthalmologic agent dispersed in at least one biodegradable polymer, wherein the polymer comprises at least one of a poly (ester amide) (PEA) having a chemical formula described by structural formula (I).
    Type: Application
    Filed: May 2, 2012
    Publication date: April 17, 2014
    Applicant: DSM IP ASSETS B.V.
    Inventors: Astrid Franken, George Mihov, Jens Christoph Thies
  • Patent number: 8686035
    Abstract: The present invention provides a method and composition for promoting hair growth in a mammal which comprises a prostaglandin compound having two hetero atoms at the 15 position as an active ingredient thereof.
    Type: Grant
    Filed: August 12, 2004
    Date of Patent: April 1, 2014
    Assignee: R-Tech Ueno, Ltd.
    Inventors: Ryuji Ueno, Tsuyoshi Habe, Takashi Sekida
  • Publication number: 20140086973
    Abstract: The present invention provides a pharmaceutical preparation comprising a layer-by-layer thin film that is produced by alternately layering a polycation and a polyanion, and a drug loaded onto the layer-by-layer thin film. As a result, a pharmaceutical preparation with a prolonged duration of drug action with a single dose is provided.
    Type: Application
    Filed: March 23, 2012
    Publication date: March 27, 2014
    Applicant: NANOTHETA CO, LTD.
    Inventors: Shinji Takeoka, Kenji Kashiwagi, Toshinori Fujie, Akihiro Saito, Hiroki Haniuda
  • Publication number: 20140088107
    Abstract: The present invention relates to an aqueous ophthalmic preparation comprising a PGF2? analogue and at least one polyvinyl alcohol and the use thereof for the treatment of glaucoma and ocular hypertension.
    Type: Application
    Filed: November 25, 2013
    Publication date: March 27, 2014
    Applicant: RATIOPHARM GMBH
    Inventors: Dieter Swatscheck, Max-Werner Scheiwe, Michael Florenski
  • Patent number: 8680078
    Abstract: Disclosed herein are stable formulations suitable for the treatment of glaucoma and ocular hypertension.
    Type: Grant
    Filed: November 7, 2008
    Date of Patent: March 25, 2014
    Assignee: Medivis SRL
    Inventors: Danilo Aleo, Sergio Mangiafico, Maria Grazia Antonietta Saita
  • Patent number: 8673973
    Abstract: Provided is a method for treating ocular hypertension and glaucoma with reduced side effects such as keratoconjunctive disorders and macular edema, which comprises administering an ophthalmic composition comprising latanoprost as an active ingredient thereof to a subject in need of said treatment, wherein the ophthalmic composition contains substantially no benzalkonium chloride.
    Type: Grant
    Filed: May 23, 2006
    Date of Patent: March 18, 2014
    Assignee: Sucampo AG (USA) Inc.
    Inventor: Ryuji Ueno
  • Patent number: 8673937
    Abstract: Disclosed is a technique for preventing the decomposition of latanoprost (a thermally unstable substance) contained in an eye-drop solution to stabilize the eye-drop solution. Specifically disclosed is an eye-drop preparation comprising latanoprost and carteolol hydrochloride. By adding carteolol hydrochloride to an eye-drop solution containing latanoprost which is a thermally unstable substance and is likely to be adhered on the surface of a container, it becomes possible to prevent the decomposition of latanoprost in the eye-drop solution and also prevent the loss of latanoprost caused by the adsorption of latanoprost on the surface of a container.
    Type: Grant
    Filed: April 23, 2009
    Date of Patent: March 18, 2014
    Assignee: Otsuka Pharmaceutical Co., Ltd.
    Inventors: Yoshinao Onishi, Shinichi Ishikawa
  • Publication number: 20140057980
    Abstract: Novel calcilytic compounds and methods of using them are provided.
    Type: Application
    Filed: November 1, 2013
    Publication date: February 27, 2014
    Applicant: GlaxoSmithKline, LLC
    Inventors: Robert W. Marquis, Linda N. Casillas, Joshi M. Ramanjulu, James Francis Callahan
  • Publication number: 20140045933
    Abstract: Provided are methods, compositions, systems, and kits for treating metabolic syndrome or a disorder associated with metabolic syndrome, e.g., obesity, dyslipidemia, and/or a diabetic condition, comprising administering systemically to a subject one or more compounds of the Formula (I) and/or (II): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, polymorph, tautomer, isotopically enriched derivative, or prodrug thereof, wherein, L, R1; R2, Z, X, A and B are defined herein.
    Type: Application
    Filed: January 18, 2012
    Publication date: February 13, 2014
    Applicant: Terakine Therapeutics, Inc.
    Inventor: Murat V. Kalayoglu
  • Publication number: 20140031423
    Abstract: The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them.
    Type: Application
    Filed: September 26, 2013
    Publication date: January 30, 2014
    Applicant: NOVAER HOLDINGS, INC.
    Inventors: Mitchell A. deLong, Jill Marie Sturdivant
  • Patent number: 8637571
    Abstract: Membrane transporter-targeted therapeutic agents and methods of making and using the same.
    Type: Grant
    Filed: March 23, 2010
    Date of Patent: January 28, 2014
    Assignee: Allergan, Inc.
    Inventors: Patrick M. Hughes, Orest Olejnik, Joan-En Chang-Lin
  • Publication number: 20140024587
    Abstract: A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.
    Type: Application
    Filed: September 23, 2013
    Publication date: January 23, 2014
    Applicant: Duke University
    Inventors: Mitchell A. deLong, John M. McIver, Robert S. Youngquist
  • Patent number: 8628798
    Abstract: A water-swellable linear polyurethane polymer is formed by reacting a polyethylene oxide (e.g. PEG 4000 to 35,000), a difunctional compound (e.g. a diamine or diol such as 1,10-decanediol) with a diisocyanate. The ratio of the three components is generally in the range 0.1-1.5 to 1 to 1.1-2.5. The polyurethane is water-swellable in the range 300 to 1700% and soluble in certain organic solvents such as dichloromethane. It can be loaded with pharmaceutically active agents, particularly of high molecular weight, to produce controlled release compositions, such as pessaries etc.
    Type: Grant
    Filed: August 10, 2012
    Date of Patent: January 14, 2014
    Assignee: Ferring B.V.
    Inventors: Janet A. Halliday, Jukka Tuominen, Mark Livingstone, Frank Koppenhagen, Lilias Currie, Sarah Stewart
  • Patent number: 8629140
    Abstract: New compositions for and methods of treating ocular hypertension provide for effective treatment of ocular hypertension often using reduced concentrations of active components. Such compositions include a timolol component and a hypotensive lipid component. The present compositions and methods are relatively straightforward, can be easily produced, for example, using conventional manufacturing techniques, and can be easily and conveniently practiced, for example, using application or administration techniques or methodologies which are substantially similar to those employed with prior compositions used to treat ocular hypertension.
    Type: Grant
    Filed: May 22, 2002
    Date of Patent: January 14, 2014
    Assignee: Allergan, Inc.
    Inventors: June Chen, David F. Woodward, Alexander B. Kharlamb
  • Patent number: 8618093
    Abstract: New compositions for and methods of treating ocular hypertension provide for effective treatment of ocular hypertension often using reduced concentrations of active components. Such compositions include a timolol component and a hypotensive lipid component. The present compositions and methods are relatively straightforward, can be easily produced, for example, using conventional manufacturing techniques, and can be easily and conveniently practiced, for example, using application or administration techniques or methodologies which are substantially similar to those employed with prior compositions used to treat ocular hypertension.
    Type: Grant
    Filed: March 20, 2009
    Date of Patent: December 31, 2013
    Assignee: Allergan, Inc.
    Inventors: June Chen, David F. Woodward, Alexander B. Kharlamb
  • Patent number: 8618086
    Abstract: A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.
    Type: Grant
    Filed: June 13, 2008
    Date of Patent: December 31, 2013
    Assignee: Duke University
    Inventors: Mitchell Anthony deLong, John McMillan McIver, Robert Scott Youngquist
  • Publication number: 20130345150
    Abstract: An ophthalmic composition comprising a polyaphron dispersion.
    Type: Application
    Filed: March 14, 2012
    Publication date: December 26, 2013
    Inventor: Fraser Steele
  • Patent number: 8609117
    Abstract: Cosmetic or pharmaceutical compositions comprising compounds of formula (I) and the corresponding salts thereof: wherein: R1 is a radical chosen from —COOR?, —CONR?R?, —CH2OR?, —COR?, —CH2R?, —SO2OR?, —PO3R?R? and —NHR?, wherein R? and R?, which may be identical or different, are defined herein; —R2 is chosen from saturated and unsaturated, linear, branched and cyclic hydrocarbon radicals comprising from 1 to 18 carbon atoms which are optionally substituted by from 1 to 5 identical or different entities chosen from —OR??, —OCOR??, —SR??, —SCOR??, NR??R??, —NHCOR??, halogen, —CN, —COOR?? and —COR??, wherein R?? and R??, which may be identical or different, are defined herein; as well as the use of these compounds, for example, to promote skin desquamation, to stimulate epidermal renewal and/or to combat the signs of skin ageing.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: December 17, 2013
    Assignee: L'Oreal S.A.
    Inventors: Christophe Boulle, Maria Dalko, Jean-Luc Leveque, Lucie Simonetti
  • Patent number: 8603502
    Abstract: Cosmetic or pharmaceutical compositions comprising compounds of formula (I) and the corresponding salts thereof: wherein: R1 is a radical chosen from —COOR?, —CONR?R?, —CH2OR?, —COR?, —CH2R?, —SO2OR?, —PO3R?R? and —NHR?, wherein R? and R?, which may be identical or different, are defined herein; R2 is chosen from saturated and unsaturated, linear, branched and cyclic hydrocarbon radicals comprising from 1 to 18 carbon atoms which are optionally substituted by from 1 to 5 identical or different entities chosen from —OR??, —OCOR??, —SR??, —SCOR??, NR??R??, —NHCOR??, halogen, —CN, —COOR?? and —COR??, wherein R?? and R??, which may be identical or different, are defined herein, as well as the use of these compounds, for example, to promote skin desquamation, to stimulate epidermal renewal and/or to combat the signs of skin ageing.
    Type: Grant
    Filed: February 3, 2003
    Date of Patent: December 10, 2013
    Assignee: L'Oreal S.A.
    Inventors: Christophe Boulle, Maria Dalko, Jean-Luc Leveque, Lucie Simonetti
  • Publication number: 20130309330
    Abstract: The present invention relates to methods and compositions for the treatment of neuropsychiatric conditions (e.g., bipolar disorder) by administration of prostaglandin or prostaglandin derivatives (e.g., latanoprost) to a subject (e.g., a human).
    Type: Application
    Filed: January 24, 2012
    Publication date: November 21, 2013
    Applicant: Inceptum Research & Therapeutics, Inc.
    Inventor: Fabrizio G. Mastronardi
  • Patent number: 8586632
    Abstract: The invention provides oleocanthal analogs and methods of using oleocanthals in various formulations including, food additives; pharmaceuticals; cosmetics; animal repellants; and discovery tools for mammalian irritation receptor genes, gene products, alleles, splice variants, alternate transcripts and the like.
    Type: Grant
    Filed: April 25, 2007
    Date of Patent: November 19, 2013
    Assignees: Monell Chemical Senses Center, The Trustees of The University of Pennsylvania
    Inventors: Catherine Peyrot Des Gachons, Jeffrey B. Sperry, Bruce Bryant, Paul A. S. Breslin, Amos B. Smith, III, Gary K. Beauchamp
  • Patent number: 8586630
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Grant
    Filed: December 14, 2012
    Date of Patent: November 19, 2013
    Assignee: Allergan, Inc.
    Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
  • Publication number: 20130303473
    Abstract: The invention provides pharmaceutical compositions based on liquid vehicles whose density is substantially higher than that of aqueous physiological fluids. The compositions are useful as medicines in ophthalmology, in particular for the treatment of conditions affecting the posterior segment of an eye. They may be administered topically into the eye or in a minimally invasive manner by periocular injection. Preferred liquid carriers are selected from semifluorinated alkanes.
    Type: Application
    Filed: November 10, 2011
    Publication date: November 14, 2013
    Applicant: NOVALIQ GmbH
    Inventor: Clive G. Wilson
  • Patent number: 8580851
    Abstract: The present invention relates to an ophthalmic solution comprising a prostaglandin compound and viscosity-increasing compound. The ophthalmic solution of the invention is excellent in stability and can provide long lasting and increased effect when administrated topically to the eyes of a patient.
    Type: Grant
    Filed: April 21, 2005
    Date of Patent: November 12, 2013
    Assignee: Sucampo AG
    Inventor: Ryuji Ueno
  • Publication number: 20130296323
    Abstract: This invention relates to geranylgeranyl acetone (GGA) derivatives and the use of GGA, its isomers, and GGA derivatives in methods for inhibiting neural death, increasing neural activity, increasing axon growth and cell viability, and increasing the survival rate of subjects administered the GGA or GGA derivatives.
    Type: Application
    Filed: February 27, 2013
    Publication date: November 7, 2013
    Applicant: COYOTE PHARMACEUTICALS, INC.
    Inventors: Hiroaki Serizawa, Ankush B. Argade, Akash Datwani, Natalie Spencer, Yonghua Pan, Florian Ermini
  • Publication number: 20130281529
    Abstract: It is intended to provide an eye drop preparation capable of preventing not only degradation of latanoprost in water but also adsorption of latanoprost onto a plastic container so that a decrease in latanoprost content thereof is satisfactorily prevented. The eye drop preparation contains an ophthalmic solution composition containing components (A) and (B) and packed in a plastic container: (A) latanoprost; and (B) a nonionic surfactant.
    Type: Application
    Filed: June 20, 2013
    Publication date: October 24, 2013
    Inventors: Takahito Kimura, Joshu Watanabe, Minoru Kobayashi, Makoto Seki, Takao Shimatani, Chiharu Takagi
  • Publication number: 20130281454
    Abstract: Compositions containing a prostaglandin agent and a vasoconstrictor agent for ophthalmic applications are provided as well as methods of treating ophthalmic diseases using the same. In certain embodiments, the compositions and methods are useful for treating glaucoma without causing conjunctival hyperemia.
    Type: Application
    Filed: April 23, 2013
    Publication date: October 24, 2013
    Applicant: ALLERGAN, INC.
    Inventors: RHETT M. SCHIFFMAN, JUNE CHEN
  • Patent number: 8563027
    Abstract: An embodiment is a medical prosthesis for blocking or reducing tear flow through a punctum or canaliculus of a human eye and delivering a drug to the eye that comprises a dehydrated covalently crosslinked synthetic hydrophilic polymer hydrogel with dimensions to pass through a puncta lacrimali, with the dehydrated hydrogel absorbing physiological water to swell to at least 1 mm in cross-sectional width and conformably fit a canaliculus, with the hydrogel comprising a therapeutic agent dispersed through the hydrogel for release to an eye, with the hydrogel having a water content of at least about 50% by weight or volume when allowed to fully hydrate in vitro in physiological saline.
    Type: Grant
    Filed: February 26, 2013
    Date of Patent: October 22, 2013
    Assignee: Incept, LLC
    Inventors: Peter Jarrett, Michael Bassett, Charles D. Blizzard, Amarpreet S. Sawhney
  • Publication number: 20130267591
    Abstract: An ophthalmic solution comprising therapeutically effective amount of a prostaglandin or its analog and water soluble excipient(s) dissolved in a pharmaceutically acceptable vehicle, wherein the solution is free of a surfactant.
    Type: Application
    Filed: May 6, 2011
    Publication date: October 10, 2013
    Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED
    Inventors: Ajay Jaysingh Khopade, Arindam Halder, Subhas Balaram Bhowmick
  • Patent number: 8552059
    Abstract: The present invention provides compositions and methods for treating an ischemic episode using misoprostol alone or in combination with anti-thrombotic agents.
    Type: Grant
    Filed: September 18, 2012
    Date of Patent: October 8, 2013
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventor: Katrin Andreasson
  • Publication number: 20130261179
    Abstract: A pharmaceutical delivery device, such as a suppository or pessary, comprises a synthetic prostaglandin PGE1 analogue (e.g. misoprostol) in a solid polyurethane hydrogel.
    Type: Application
    Filed: May 31, 2013
    Publication date: October 3, 2013
    Inventor: Steven Robertson
  • Patent number: 8541466
    Abstract: A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: September 24, 2013
    Assignee: Duke University
    Inventors: Mitchell Anthony DeLong, John McMillan McIver, Robert Scott Youngquist
  • Publication number: 20130245018
    Abstract: The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain aryl-phenyl-sulfonamido-cycloalkyl compounds of the following formula (collectively referred to herein as “APSAC compounds”).
    Type: Application
    Filed: May 3, 2013
    Publication date: September 19, 2013
    Applicant: PIMCO 2664 LIMITED
    Inventors: Iain Robert Greig, Rose Mary Sheridan, Raymond Fisher, Matthew John Tozer, Juha Andrew Clase, Andrew Smith, Andrew Robert Tuffnell, Robert Jurgen Van 't Hof
  • Publication number: 20130237573
    Abstract: A mGlu2/3 receptor antagonist of the formula: its uses, and methods for its preparation are described.
    Type: Application
    Filed: November 15, 2011
    Publication date: September 12, 2013
    Applicant: ELI LILLY AND COMPANY
    Inventors: Bruce Anthony Dressman, Mark Donald Chappell, Adam Michael Fivush, Charles Howard Mitch, Paul Leslie Ornstein, Eric George Tromiczak, Tatiana Natali Vetman
  • Publication number: 20130236557
    Abstract: Biocompatible intraocular implants, such as microparticles, include a prostamide component and a biodegradable polymer that is effective in facilitating release of the prostamide component into an eye for an extended period of time. The prostamide component may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the prostamide component may be encapsulated by the ploymeric component. The present implants include oil-in-oil emulsified implants or microparticles. Methods of producing the present implants are also described. The implants may be placed in eye to treat or reduce a at least one symptom of an ocular condition, such as glaucoma.
    Type: Application
    Filed: April 12, 2013
    Publication date: September 12, 2013
    Applicant: Allergan, Inc.
    Inventors: Patrick M. Hughes, Michele Boix, Christian Sarrazin, Marina Do
  • Patent number: 8524777
    Abstract: A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein. A method which is useful in treating glaucoma or ocular hypertension related thereto is also disclosed herein.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: September 3, 2013
    Assignee: Allergan Inc.
    Inventors: Chin-Ming Chang, James N. Chang, Rhett M. Schiffman, R. Scott Jordan, Joan-En Chang-Lin
  • Patent number: 8524771
    Abstract: The invention provides compositions and methods that employ compounds that can stimulate proliferation of fibroblasts or keratinocytes and/or stimulate production of collagen by fibroblasts. These compositions and methods are useful for treating gum- and skin-related conditions.
    Type: Grant
    Filed: November 23, 2010
    Date of Patent: September 3, 2013
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventor: Sohail Malik
  • Publication number: 20130217767
    Abstract: The present invention concerns a cosmetic composition comprising the following fluorinated analog of prostaglandin F2?: The cosmetic composition may further comprise a complexing agent and/or a humectant. The present invention further relates to a cosmetic kit, comprising the cosmetic composition and an applicator for application thereof.
    Type: Application
    Filed: March 21, 2013
    Publication date: August 22, 2013
    Applicant: S & V Technologies AG
    Inventor: S & V Technologies AG
  • Publication number: 20130216606
    Abstract: The present invention is directed to a liposomal formulation for ocular drug delivery comprising (i) liposomes comprising at least one lipid bilayer, and (ii) a prostaglandin drug and/or a prostaglandin derivative associated in the liposomes, wherein the liposomes have a mean diameter of less than 2???. The present invention is also directed to a pharmaceutical comprising the liposomal formulation and a method of producing the liposomal formulation for ocular drug delivery. Additionally, the present invention is directed to a method of treating or preventing an ocular disease, comprising administering the liposomal formulation or the pharmaceutical composition to a subject in need thereof.
    Type: Application
    Filed: August 12, 2011
    Publication date: August 22, 2013
    Applicants: SINGAPORE HEALTH SERVICES PTE LTD, NANYANG TECHNOLOGICAL UNIVERSITY
    Inventors: Subramanian Venkatraman, Jayaganesh V. Natarajan, Tina Wong, Yin Chiang Freddy Boey